VivoSeq
Other

Hematopoietic Cell Transplantation

0

Pipeline Programs↗

6

Active Trials↗

0

Companies Involved↗

Hematopoietic Cell Transplantation is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

80/100

Attrition Rate

14/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

22

clinical trials

Completed12 · 55%
Recruiting4 · 18%
Terminated3 · 14%
Active, not recruiting2 · 9%
Unknown status1 · 5%

Clinical Trials

Trial Activity

22 trials

Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation
Recruiting·HHenry Ford Health System·Phase 3·NCT05509933·110 enrolled
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Recruiting·—·Phase 1·NCT04024761·50 enrolled
Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell Transplantation
Recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT05664126·42 enrolled
Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Recruiting·WWashington University School of Medicine·Phase 1·NCT06008808·41 enrolled
A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03556332·41 enrolled
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
Active, not recruiting·CCenter for International Blood and Marrow Transplant Research·Phase 2·NCT04904588·300 enrolled
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
Completed·SStanford University·Phase 2·NCT03734601·22 enrolled
Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer
Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04478123·62 enrolled
Safety and Tolerability of Intravenous Fish Oil Lipid Emulsion in Children Undergoing Hematopoietic Cell Transplantation
Completed·—·Phase 1·NCT02512718·20 enrolled
Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies
Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00521859·5 enrolled
Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation
Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT02074631·63 enrolled
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Completed·WWashington University School of Medicine·Phase 1·NCT03755414·55 enrolled
Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation
Completed·WWashington University School of Medicine·Phase 1·NCT04131738·26 enrolled
Hematopoietic Cell Transplantation With Post-transplantation Cyclophosphamide in MDS
Completed·—·Phase 2·NCT02969980·30 enrolled
Safety Evaluation of Intramuscular Injections of PLX-R18 in Subjects With Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation
Completed·PPluristem Ltd.·Phase 1·NCT03002519·21 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)